Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is ...

today announced that it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae), its fourth assay on the illumigene platform. This innovative test that ...

Meridian Bioscience, Inc. has announced that it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene® Mycoplasma ...

If your child has a cough that just won't go away, it could be mycoplasma pneumonia. Doctors say they are seeing a significant uptick in the amount of people, especially children, with the bacterial ...

Often referred to as “walking pneumonia”, M. pneumoniae has been associated with up to 40% of community-acquired pneumonias. Infection occurs in both children and adults without geographical, gender ...

Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene ® Mycoplasma Meridian is a fully integrated life science company that develops, manufactures, markets and ...

Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene ® Mycoplasma CINCINNATI--(BUSINESS WIRE)-- Meridian Bioscience, Inc., Cincinnati, Ohio (NAS: VIVO) today ...